Pre-made Palivizumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-423

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-423 Category Tag

Product Details

Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.

Products Name (INN Index)

Pre-Made Palivizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody

INN Name

Palivizumab

Target

RSV gpF

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

NFD

100% SI Structure

None

99% SI Structure

2hwz:HL

95-98% SI Structure

None

Year Proposed

1998

Companies

MedImmune

Conditions Approved

Respiratory syncytial virus infections

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

GS Gene Expression System

Previous Name

NA

Gm Offical Target Name

RSV gpF

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide